2024
Understanding and overcoming resistance to immunotherapy in genitourinary cancers
Evans S, Jani Y, Jansen C, Yildirim A, Kalemoglu E, Bilen M. Understanding and overcoming resistance to immunotherapy in genitourinary cancers. Cancer Biology & Therapy 2024, 25: 2342599. PMID: 38629578, PMCID: PMC11028033, DOI: 10.1080/15384047.2024.2342599.Peer-Reviewed Original ResearchConceptsImmune checkpoint inhibitorsResistance to immunotherapyImmunotherapy resistanceTargeted therapyGenitourinary (GU) cancersCombined immune checkpoint inhibitorsIntroduction of novel immunotherapiesMechanisms of immunotherapy resistanceOvercome resistance to immunotherapyCancer cellsHost immune profileResponse to immunotherapyNovel targeted therapiesImmune system's rolePredictors of responseAttack cancer cellsImmune system's abilityStandard of careCheckpoint inhibitorsSequential therapyNovel immunotherapiesCombination therapyTreatment failureGU cancersTreatment landscapeImpact of immunotherapy time-of-day infusion on survival and immunologic correlates in patients with metastatic renal cell carcinoma: a multicenter cohort analysis
Patel J, Woo Y, Draper A, Jansen C, Carlisle J, Innominato P, Lévi F, Dhabaan L, Master V, Bilen M, Khan M, Lowe M, Kissick H, Buchwald Z, Qian D. Impact of immunotherapy time-of-day infusion on survival and immunologic correlates in patients with metastatic renal cell carcinoma: a multicenter cohort analysis. Journal For ImmunoTherapy Of Cancer 2024, 12: e008011. PMID: 38531662, PMCID: PMC10966813, DOI: 10.1136/jitc-2023-008011.Peer-Reviewed Original ResearchConceptsInfusions of immune checkpoint inhibitorsMetastatic renal cell carcinomaProgression-free survivalOverall survivalRenal cell carcinomaCell carcinomaInternational Metastatic RCC Database Consortium risk scoreAssociated with longer progression-free survivalLung cancerGroup BGroup ATime of ICI initiationLonger progression-free survivalNon-small cell lung cancerMultivariable Cox proportional hazards regressionImmune checkpoint inhibitorsPretreatment lactate dehydrogenaseCell lung cancerCox proportional hazards regressionAdaptive immune responsesProportional hazards regressionMulticenter cohort analysisCheckpoint inhibitorsICI initiationMetastatic melanomaEstablished and Emerging Biomarkers of Immunotherapy in Renal Cell Carcinoma
Jani Y, Jansen C, Gerke M, Bilen M. Established and Emerging Biomarkers of Immunotherapy in Renal Cell Carcinoma. Immunotherapy 2024, 16: 405-426. PMID: 38264827, DOI: 10.2217/imt-2023-0267.Peer-Reviewed Original ResearchConceptsRenal cell carcinomaCell carcinomaImmune checkpoint inhibitorsBiomarker of immunotherapyRisk of adverse eventsSignificant side effectsCheckpoint inhibitorsDevelopment of biomarkersAdverse eventsImmunotherapyTherapeutic efficacySide effectsPatientsClinical biomarkersPatient's diseaseTherapeutic biomarkersClinician's abilityBiomarkersCarcinomaPatient careImproving clinicians' abilityEfficacyThe Evolving Landscape of Biomarkers for Immune Checkpoint Blockade in Genitourinary Cancers
Mustafa S, Jansen C, Jani Y, Evans S, Zhuang T, Brown J, Nazha B, Master V, Bilen M. The Evolving Landscape of Biomarkers for Immune Checkpoint Blockade in Genitourinary Cancers. Biomarker Insights 2024, 19: 11772719241254179. PMID: 38827239, PMCID: PMC11143877, DOI: 10.1177/11772719241254179.Peer-Reviewed Original ResearchImmune-related adverse eventsImmune checkpoint inhibitorsResponse to immunotherapyAdverse eventsTreatment of genitourinary malignanciesImmune checkpoint blockadeSelection of therapySignificant side effectsCheckpoint blockadeCheckpoint inhibitorsGU malignanciesGenitourinary malignanciesPatient tumorsTreatment landscapeReview of biomarkersGenitourinary cancersGU tumorsPreclinical studiesPrognostic toolSide effectsTherapyBiomarker developmentTumorPatientsImmunotherapy
2021
Case Report: Exceptional Response to Nivolumab Plus Ipilimumab in a Young Woman With TFE3-SFPQ Fusion Translocation-Associated Renal Cell Carcinoma
Martini D, Jansen C, Harik L, Evans S, Olsen T, Master V, Kissick H, Bilen M. Case Report: Exceptional Response to Nivolumab Plus Ipilimumab in a Young Woman With TFE3-SFPQ Fusion Translocation-Associated Renal Cell Carcinoma. Frontiers In Oncology 2021, 11: 793808. PMID: 34976834, PMCID: PMC8716393, DOI: 10.3389/fonc.2021.793808.Peer-Reviewed Original ResearchCD8+ T cellsResponse to treatmentT cellsLymphovascular invasionTranslocation-associated renal cell carcinomaFoci of lymphovascular invasionBiomarker of response to treatmentRadiographic response to treatmentFirst-line treatment optionFavorable response to treatmentIntratumoral immune infiltrationImmune checkpoint inhibitorsResponse to nivolumabRenal cell carcinomaPrimary tumor samplesYear old femalePresence of lymphocytesCheckpoint inhibitorsProgression-freeRare malignancyCell carcinomaPredictive biomarkersImmune infiltrationAggressive malignancyTreatment optionsA Subset of Localized Prostate Cancer Displays an Immunogenic Phenotype Associated with Losses of Key Tumor Suppressor Genes
Calagua C, Ficial M, Jansen C, Hirz T, Del Balzo L, Wilkinson S, Lake R, Ku A, Voznesensky O, Sykes D, Saylor P, Ye H, Signoretti S, Kissick H, Sowalsky A, Balk S, Einstein D. A Subset of Localized Prostate Cancer Displays an Immunogenic Phenotype Associated with Losses of Key Tumor Suppressor Genes. Clinical Cancer Research 2021, 27: 4836-4847. PMID: 34168052, PMCID: PMC8416924, DOI: 10.1158/1078-0432.ccr-21-0121.Peer-Reviewed Original ResearchConceptsRenal cell carcinomaCD8<sup>+</sup> T cellsImmune checkpoint inhibitorsPD-L1 expressionLocalized prostate cancerPrimary prostate cancerProstate cancerT cellsPD-L1Density of CD8<sup>+</sup> T cellsHigh-risk primary prostate cancerCD8 T-cell densityCharacterized tumor infiltrating lymphocytesLocalized prostate cancer casesPD-1<sup>+</sup> cellsTumor PD-L1 expressionUnique tumor immune microenvironmentPD-1 expressionTumor-infiltrating lymphocytesT-cell densityCD8 T cellsTumor immune microenvironmentTumor mutational burdenProstate cancer casesT-cell content